| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
104,690,000 |
| Market
Cap: |
108.27(B) |
| Last
Volume: |
418,302 |
Avg
Vol: |
758,271 |
| 52
Week Range: |
$692.45 - $1071.19 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
S&P SMALLCAP 600 |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 150 |
| Guru Rank Value : 6.9 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Co.'s products include: EYLEA (aflibercept) Injection, which is used for the treatment of neovascular age-related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion, myopic choroidal neovascularization, diabetic retinopathy, and neovascular glaucoma; REGEN-COV, which is used for the treatment of COVID-19; and Kevzara (sarilumab) Solution for Subcutaneous Injection, which is used for the treatment of rheumatoid arthritis.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
192,995 |
237,237 |
312,646 |
469,880 |
| Total Sell Value |
$189,656,342 |
$231,855,596 |
$295,997,978 |
$406,115,303 |
| Total People Sold |
7 |
13 |
16 |
18 |
| Total Sell Transactions |
18 |
40 |
67 |
129 |
| End Date |
2024-04-07 |
2024-01-05 |
2023-07-07 |
2022-07-07 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Goldberg Murray A |
SVP F&A, CFO, Treas & Asst Sec |
• – – |
2010-12-16 |
4 |
D |
$31.80 |
$352,408 |
D/D |
(11,082) |
48,902 |
|
- |
|
| Goldberg Murray A |
SVP F&A, CFO, Treas & Asst Sec |
• – – |
2010-12-16 |
4 |
OE |
$13.00 |
$211,250 |
D/D |
16,250 |
59,984 |
|
- |
|
| Stahl Neil |
SVP Res and Dev Sciences |
• – – |
2010-12-14 |
4/A |
A |
$0.00 |
$0 |
D/D |
50,000 |
50,350 |
|
- |
|
| Yancopoulos George |
EVP CSO & Pres Regn Res Labs |
• • – |
2010-12-14 |
4/A |
A |
$0.00 |
$0 |
D/D |
250,000 |
870,375 |
|
- |
|
| Goldberg Murray A |
SVP F&A, CFO, Treas & Asst Sec |
• – – |
2010-12-14 |
4/A |
A |
$0.00 |
$0 |
D/D |
30,000 |
73,734 |
|
- |
|
| Goldstein Joseph L |
Director |
– • – |
2010-11-24 |
4 |
AS |
$30.06 |
$130,190 |
D/D |
(4,331) |
0 |
|
- |
|
| Goldstein Joseph L |
Director |
– • – |
2010-11-23 |
4 |
D |
$29.81 |
$168,993 |
D/D |
(5,669) |
4,331 |
|
- |
|
| Goldstein Joseph L |
Director |
– • – |
2010-11-23 |
4 |
OE |
$15.01 |
$169,050 |
D/D |
10,000 |
6,848 |
|
- |
|
| Vagelos P Roy |
Director |
– • – |
2010-11-23 |
4 |
AS |
$30.03 |
$900,900 |
D/D |
(30,000) |
170,512 |
|
- |
|
| Shooter Eric M |
Director |
– • – |
2010-11-23 |
4 |
AS |
$30.00 |
$225,000 |
D/D |
(7,500) |
0 |
|
- |
|
| Shooter Eric M |
Director |
– • – |
2010-11-23 |
4 |
OE |
$19.69 |
$147,675 |
D/D |
7,500 |
7,500 |
|
- |
|
| Gilman Alfred G |
Director |
– • – |
2010-10-21 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,000 |
1,922 |
|
- |
|
| Gilman Alfred G |
Director |
– • – |
2010-10-20 |
4 |
GD |
$0.00 |
$0 |
D/D |
9,000 |
2,922 |
|
- |
|
| Sanofi-Aventis Amerique Du Nord S.n.c. |
10% Owner |
– – • |
2010-10-13 |
4 |
B |
$28.00 |
$28,487,228 |
I/I |
1,017,401 |
15,816,953 |
1.5 |
- |
|
| Brown Michael S |
Director |
– • – |
2010-10-07 |
4 |
AS |
$28.03 |
$49,473 |
D/D |
(1,765) |
29,662 |
|
- |
|
| Brown Michael S |
Director |
– • – |
2010-10-06 |
4 |
D |
$29.05 |
$93,977 |
D/D |
(3,235) |
31,427 |
|
- |
|
| Brown Michael S |
Director |
– • – |
2010-10-06 |
4 |
OE |
$18.80 |
$94,000 |
D/D |
5,000 |
34,662 |
|
- |
|
| Goldstein Joseph L |
Director |
– • – |
2010-10-05 |
4 |
D |
$28.40 |
$89,517 |
D/D |
(3,152) |
0 |
|
- |
|
| Vagelos P Roy |
Director |
– • – |
2010-10-04 |
4 |
GD |
$0.00 |
$0 |
I/I |
8,035 |
190,119 |
|
- |
|
| Goldstein Joseph L |
Director |
– • – |
2010-10-04 |
4 |
D |
$27.45 |
$187,978 |
D/D |
(6,848) |
3,152 |
|
- |
|
| Goldstein Joseph L |
Director |
– • – |
2010-10-04 |
4 |
OE |
$18.80 |
$188,000 |
D/D |
10,000 |
10,000 |
|
- |
|
| Roberts William |
VP Regul Devel & Med Safety |
• – – |
2010-07-15 |
4 |
GA |
$0.00 |
$0 |
I/I |
8,041 |
16,147 |
|
- |
|
| Vagelos P Roy |
Director |
– • – |
2010-07-07 |
4 |
A |
$0.00 |
$0 |
I/I |
125,000 |
125,000 |
|
- |
|
| Vagelos P Roy |
Director |
– • – |
2010-07-07 |
4 |
D |
$0.00 |
$0 |
D/D |
(125,000) |
435,512 |
|
- |
|
| Vagelos P Roy |
Director |
– • – |
2010-07-02 |
4 |
GD |
$0.00 |
$0 |
I/I |
9,021 |
198,154 |
|
- |
|
2433 Records found
|
|
Page 80 of 98 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
10.14 (0.99%) 
